Articles About Medtech

A 263% Growth Spurt Is Just the Beginning for This MedTech Trailblazer

0 | By Michael A. Robinson

We recently passed the one-year anniversary of a bold call I made about a MedTech leader that was inspired by a reality show.

On June 20, 2020 this pioneer in aesthetic medicine was still flying under Wall Street’s radar.

And that’s just fine with us. As savvy tech investors we know all too well that by beating the so-called “pros” to the punch, we set ourselves up to really crush the market.

Since then, the S&P 500 has risen 39.8% in a historic run, which is nice and all, but the firm I recommended last June smoked those returns by a stunning 560.8%.

As a major disruptor in the plastic surgery market, this firm’s stock is way ahead of my forecast and has actually gained 263% for a nearly four-fold increase in 13 months.

Even with this much growth, I see plenty of upside ahead.

Let me show you why there’s at least another double in the making…

This Franchise’s Stock Will Double While Riding This Unstoppable Healthcare Trend

0 | By Michael A. Robinson

I can say from personal experience that home health care for seniors and hospice services are a godsend to millions.

And not just because there’s a lot of money up for grabs. More on that in a moment.

Here’s the thing. I recently mentioned that my father passed away after a battle with congestive heart failure.

We were fortunate to be able to find a crackerjack health team to work with him in his Virginia home. In fact, they were with him when he passed away on May 27.

So, I know first-hand that these services can bring big emotional payoffs.

More than just an essential service, home healthcare is also a very lucrative field that continues to grow alongside a national trend.

Analysts say the home health care market to be worth $225 billion by 2024.

Today, I’m going to reveal a leader in this field whose stock could double in less than three years…

This Medtech Leader Is Coming Back From Covid

0 | By Michael A. Robinson

After all the trouble that Covid caused for the med-tech sector, one innovative leader is on its way to coming back better than ever. Nothing proves that better than their recent beat-and-raise quarter.

For the March quarter, the firm earned $3.52 per share, up 31% and crushing forecasts. Analysts had expected per-share profits of $2.64, or 25 less than the actual results.

With the Covid recovery underway, the company raised guidance for the full year. It now expects growth in robotic procedures of as much as 26% for all of 2021, compared with Wall Street’s 18% forecast.

This medtech firm specializes in sophisticated gear for robotic surgeries, during Covid, a huge amount of the $1.1 trillion US healthcare market was focused on treating coronavirus cases.

That meant that elective surgeries for the fiscal year ended in March were pretty much out the window, and the companies that target them fell out of favor.

But now, all of that is in the rearview mirror.

Instead, this company just reminded tech investors of the great value proposition here by easily beating Wall Street forecasts.

With that news as a spark, the stock jumped 9.9% in a single session on May 21. It’s now back in a nice uptrend.

Let me show you why this good news means this company is just getting started…

When This Company Reports Earnings, We’ll Win No Matter How It Goes

0 | By Michael A. Robinson

Coming up next month, we’re about to have a golden opportunity to see a key aspect of my investing philosophy in action.

Just because Wall Street might panic after catching a scrap of bad news doesn’t change the fundamental outlook of an investment.

There’s no better time to keep than in mind than right now, with a firm I’ve been keeping my eye on about to report earnings.

That report is giving us a chance to repeat a big win that I called back on July 26 of 2019, when I brought you a medtech leader that I still believed in, even when their stock had just gotten throttled.

Bear in mind, I made that call the day after the company lost more than 25% of its value in a single session. I still believed in them then, and I was right. Since then, they’ve offered a potential 191% return.

Over the years, I’ve found that out-of-favor tech stocks can present huge buying opportunities because, after 37 years of experience in Silicon Valley, I know the lay of the land

And now, with their earnings report coming up next month, let me show you five very important reasons why I still believe in this company just as much as ever

Everyone Is Wrong Once Again About Teledoc – Here’s How We’re Turning Those Mistakes Into Our Gains

0 | By Michael A. Robinson

On August 25, 2020, I said that there was a fire sale you as a savvy tech investor could take advantage of with Teledoc Health Inc. (TDOC).

Wall Street analysts were worried about Teledoc buying Livongo Health Inc. (LVGO) and the $18.5 billion price tag. But I know this was a big move that would add to TDOC’s lead in the shift to telemedicine.

Livongo makes devices that allow healthcare providers to remotely monitor health metrics such as blood pressure, blood sugar, weight, even behavioral health. Together they allow physicians and nurses to speak to patients remotely while having the most up-to-date information on their health.

I made it clear back then that I expected Teledoc Health Inc. (TDOC) to bounce back and beat the market.

From the day shares hit a bottom on November 10 to its recent high on February 19, TDOC zoomed some 69.6%.

Over that period, it crushed the S&P 500 by a stunning 640%.

Now, history is repeating itself, and this massive profit opportunity is coming back around. The stock is grossly oversold once again, and I see a similar setup in the making as the firm disrupts the $1.3 trillion medical market.

Here’s the thing.

According to a survey from The Harris Poll, 65% of consumers surveyed plan to use telehealth services more often after the pandemic, putting paid to Wall Street’s ridiculous notion that we’re just itching to go back to the doctor’s office.

This is still a move well worth making.

Let me show you what’s really going on and how you can clean up from Wall Street’s mistake…

Wall Street is Counting Out the Biggest Breakthrough in Medicine – Here’s How to Make Their Mistake into Your Gain

0 | By Michael A. Robinson

When Wall Street overreacts and goes right, you can make a fortune by avoiding the noise and going in the opposite direction.

In the latest edition of wild overreactions, Cathie Wood, the top-notch ETF manager of Ark Investment Management, received some flak from The Wall Street Journal.

I’ll have more on that in just a bit and why it is totally off the mark.

But make no mistake. Wood has an uncanny eye for finding breakout stocks with a market-beating track record to prove it.

One particular feather in Wood’s cap is an ETF that she runs focusing on the cutting-edge field of genomics, a tech that basically didn’t exist just a decade ago.

Without genomics, we wouldn’t have been able to understand the structure of the coronavirus. Not only that, but the first two vaccines approved both relied on a hot new segment of genomics.

And this is an industry that is projected to multiply from $18.85 billion in 2019 to $82.60 billion in 2027, according to Fortune Business Insights. That’s more than 300% growth in less than a decade.

I’ll give you more details in a moment. But first, I want to point out the sizzling returns that Wood has amassed.

Over roughly the past year, Wood’s fund beat the market by a stunning 471%.

Let me show you why this play is just getting started…

The Perfect Small Stock for Playing the $72 Billion Digital Healthcare Sector

0 | By Alex Kagin

Of all the changes the ongoing coronavirus pandemic forced on us, the change in healthcare has got to be one of the most profound.

Whether we’re managing a chronic condition, like high blood pressure, say, or an acute illness like strep throat, the market demand for healthcare needs hasn’t decreased a bit, but COVID-19 has made getting in to see a primary or specialist physician a lot more complicated and, in some cases, a lot riskier.

That means telemedicine, and the broader field of digital healthcare, are the name of the game right now. The $20 billion Teledoc-Livongo merger is proof of that.

Continue reading…

This Med-Tech Breakthrough Nearly Tripled the Market’s Returns, And It’s About to Go Even Higher

0 | By Michael A. Robinson

A very profitable chat we had back on May 19 is coming up on another chance to pay off right now

At the time I told you about a medical device leader that had just received approval for a Covid-19 test, and shot up 120% in two months.

But this is not just a COVID testing play. From early 2019 through this past February’s correction, this stock was outperforming the S&P 500 by an astonishing 278.5%.

This firm is a leader in the medical device market as part of a trend toward remote patient monitoring that’s been supercharged by the COVID pandemic.

With the coronavirus surging once again, the investment thesis is only getting better.

Today, I will reveal the name of this market crushing leader and show you why there ‘s still so much upside ahead…

Americans Have A New Way of Dealing with Lockdowns – And It’s Supercharging the Market for This Company’s Products

0 | By Michael A. Robinson

Hearing that two of my neighbors had each gotten a new dog in one week may not sound like much.

But to me, those were important data points in a much larger trend. According to TD Ameritrade, 33% of Americans have considered getting a new pet to help keep them company amidst COVID restrictions.

They actually spell Big Money for savvy tech investors – if you know where to look.

I know this from personal experience. I follow the animal health care market because my dog, Roxy, has a bit of arthritis and may soon need to start a course of drugs.

And this knowledge can not only help America’s pet owners care for their companions but also find the hidden profit potential in animal healthcare technology.

It’s a growing market, as with much of the nation still working or attending school from home, demand for dogs is booming.

Consider that the U.S alone already boasts 300 million pets. Related health care on a global basis last year will soon be worth $327 billion.

Today, I’m going to reveal a leader in this key field of animal science that’s proven it can outperform the broader market by 50%…

This Life-Saving Breakthrough Is Saving COVID Patient’s Hearts and Giving You The Opportunity To Take Advantage Of A Projected $600 Billion Industry

1 | By Michael A. Robinson

Devan Smith had one foot in the grave.

After contracting COVID-19 last May, he was hospitalized with severe respiratory issues and multiorgan failure.

And if that wasn’t bad enough, the 42-year Pennsylvania warehouse worker also had to deal with a malfunctioning heart. That alone could have killed him.

But doctors at the Mercy Catholic Medical Center in Pennsylvania were able to save Smith in no small measure because of a tiny heart pump.

Known as the Impella, that device received an emergency use authorization from the FDA to treat coronavirus patients only weeks before.

Of course, Smith credits the medical team with saving his life. But he’s quick to point out that the Impella played a big role in it all.

And Bill is not alone.

These kinds of heart complications are reported to affect as many as 10% of COVID-19 patients.

Fortunately for tech investors, there’s a lot more going on here than a feel-good feature story.

The medical device market is worth $625 billion, and the company behind Impella can grab a big chunk of that.

And make you a lot of money…